2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular …
S Halvorsen, J Mehilli, S Cassese, TS Hall… - European heart …, 2022 - academic.oup.com
Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …
evidence shows that it can be considered medically appropriate to a given condition and if …
Acute coronary syndromes
BA Bergmark, N Mathenge, PA Merlini… - The Lancet, 2022 - thelancet.com
Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …
coronary syndromes, cardiovascular disease remains the leading cause of death globally …
2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes
C Laudani, A Greco, G Occhipinti, S Ingala… - Cardiovascular …, 2022 - jacc.org
Objectives The aim of this study was to compare short dual antiplatelet therapy (DAPT) and
de-escalation in a network meta-analysis using standard DAPT as common comparator …
de-escalation in a network meta-analysis using standard DAPT as common comparator …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - academic.oup.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium
D Capodanno, R Mehran, MW Krucoff, U Baber… - Circulation, 2023 - Am Heart Assoc
Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or
ischemic events in patients with coronary artery disease treated with percutaneous coronary …
ischemic events in patients with coronary artery disease treated with percutaneous coronary …
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis
M Valgimigli, PC Smits, E Frigoli… - European heart …, 2022 - academic.oup.com
Aim To assess the effects of 1-or≥ 3-month dual antiplatelet therapy (DAPT) in high
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
Background It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …
Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside
J Nicolas, CA Pivato, M Chiarito… - Cardiovascular …, 2023 - academic.oup.com
Coronary stents have revolutionized the treatment of coronary artery disease. Compared
with balloon angioplasty, bare-metal stents (BMSs) effectively prevented abrupt vessel …
with balloon angioplasty, bare-metal stents (BMSs) effectively prevented abrupt vessel …